GFCAS12
LIVE

Serial Number

88862249

Owner

G+FLAS Life Sciences, Inc.

Attorney

Jun-Hwa Jeong

Filing Date

Apr 7, 2020

Add to watchlist:

No watchlists yet
View on USPTO

GFCAS12 Trademark

Serial Number: 88862249 • Registration: 6344786

GFCAS12 is a trademark filed by G+FLAS Life Sciences, Inc. on April 7, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

G+FLAS Life Sciences, Inc.

1F, 38, Nakseongdae-ro, Gwanak-gu
Seoul 08790 , KR

Entity Type: 03

Trademark Details

Filing Date

April 7, 2020

Registration Date

May 11, 2021

Published for Opposition

February 23, 2021

Goods & Services

Veterinary diagnostic reagents for use in veterinary genetic testing; Diagnostic preparations for veterinary purposes; Enzymes for medical purposes for genome editing-based therapy; Genome editing-based treatment preparations in the nature of preparations for detecting mutation in genes for medical purposes; Protein arrays for medical diagnostic purposes; Biological preparations for the treatment of cancers, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, diabetes, multiple sclerosis, heart attack, systemic lupus erythematous, age-related macular degeneration, diabetic retinopathy, prevention of pneumonia, anemia, chronic migraine, hepatitis B, hemophilia, respiratory syncytial virus (RSV) prophylaxis, HPV prevention, varicella virus vaccine, growth hormone deficiency, osteoporosis, allergic asthma, chronic idiopathic urticaria, infertility, prevention of meningococcal disease, cystic fibrosis, paroxysmal nocturnal hemoglobinuria, autoimmune diseases infectious diseases for medical or veterinary purposes; Cultures of microorganisms for medical purposes; Cells for medical purposes; Reagents for use in medical genetic testing; Stem cells for medical purposes; Diagnostic preparations for medical purposes; Medicinal protein in the nature of protein arrays for medical diagnostic purposes; Medicinal enzymes; Medicines for human purposes and medicines for animals in the nature of medicines for cancers, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, diabetes, multiple sclerosis, heart attack, systemic lupus erythematous, age-related macular degeneration, diabetic retinopathy, prevention of pneumonia, anemia, chronic migraine, hepatitis B, hemophilia, respiratory syncytial virus (RSV) prophylaxis, HPV prevention, varicella virus vaccine, growth hormone deficiency, osteoporosis, allergic asthma, chronic idiopathic urticaria, infertility, prevention of meningococcal disease, cystic fibrosis, paroxysmal nocturnal hemoglobinuria, autoimmune diseases, infectious diseases; Surgical implants grown from stem cells in the nature of surgical implants comprised of living tissue; Pharmaceutical preparations for genome editing-based therapy of rare inherited disorders; Ferments for medical or veterinary use; Preparations for detecting mutation in genes for medical purposes; Nucleic acid sequences for medical and veterinary purposes; Enzymes for medical purposes

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
May 11, 2026 REM1
REGISTERED-PRINCIPAL REGISTER
May 11, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 23, 2021 NPUB
PUBLISHED FOR OPPOSITION
Feb 23, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 3, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 16, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 29, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 28, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 28, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 2, 2020 GNRN
NON-FINAL ACTION E-MAILED
Jul 2, 2020 GNRT
NON-FINAL ACTION WRITTEN
Jul 2, 2020 CNRT
ASSIGNED TO EXAMINER
Jun 25, 2020 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 13, 2020 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 13, 2020 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 13, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 13, 2020 REAP
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 14, 2020 NWOS
NEW APPLICATION ENTERED
Apr 10, 2020 NWAP